Skip to main content
. 2022 Jun 22;81:104109. doi: 10.1016/j.ebiom.2022.104109

Figure 4.

Figure 4

Evaluation of anti-S IgG Fc fucosylation in plasma of convalescent COVID-19 blood donors. a, Pearson's correlation of anti-spike IgG Fc fucosylation measured by FEASI and LC-MS. All samples (n = 145) were tested in both the IgG and the FcγR-IgG ELISA with two independent replicate measurements. Red and orange colours indicate samples with high galactose (>60%), according to the indicated colour scale. b, Linear regression model for the ratio of FcγR-IgG and IgG ELISA done on plasma from COVID-19 convalescent blood donors compared to anti-S IgG Fc fucosylation percentage as determined by LC-MS. Shown are 95% confidence intervals for both the slope and the y-intercept. c, Comparison between fucosylation percentage measurements by FEASI and LC-MS expressed as Bland-Altman plot. Horizontal dotted lines represent 95% limits of agreement ranging from 4.15 to -3.82% difference. The x-axis represents the geometric mean of FEASI and LC-MS measured anti-S fucosylation. d, Anti-spike IgG Fc fucosylation in COVID-19 convalescent plasma samples (n = 145) compared to the anti-spike IgG quantity of each sample. Samples obtained from blood donors treated at the ICU are shown with red triangles, samples from blood donors who have been hospitalized are shown with blue dots, and grey squares represent samples from blood donors who have not been admitted to the hospital. The vertical dotted line indicates anti-spike IgG level equal to 100 AU.